GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Guangdong Zhongsheng Ruichuang Pharmaceutical Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, ...

MIT engineers have developed a tiny implantable device that could revolutionize emergency treatment for people with Type 1 ...

These receptors also have a large cytoplasmic loop that is involved in receptor biosynthesis, assembly, transport, clustering, anchoring and modulation, but its structure is outside the scope of ...

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...

Glucan-mediated trained immunity activates alveolar macrophages which exacerbates acute lung injury induced by LPS.

Inventiva’s lanifibranor has been tipped to become a blockbuster in the liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.

Nicotinic receptors — a family of ligand-gated ion channels that mediate the effects of the neurotransmitter acetylcholine — are among the most well understood allosteric membrane proteins ...

Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...